Health Care & Life Sciences » Biotechnology | AEterna Zentaris Inc.

AEterna Zentaris Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
6,362.70
12.10
697.30
1,207.00
1,198.10
34,841.80
Cost of Goods Sold (COGS) incl. D&A
1,030.40
766.50
346.70
-
-
2,804.90
Gross Income
5,332.30
754.30
350.50
-
-
32,036.90
SG&A Expense
34,175.90
37,739.20
43,328.60
39,815.20
31,026.30
19,258.20
EBIT
28,843.70
38,493.60
42,978.10
38,866.60
30,007.40
12,778.70
Unusual Expense
1,610.50
17,228.40
15,697.90
5,691.90
2,941.30
1,473.70
Non Operating Income/Expense
1,558.00
2,075.30
5,796.90
92.70
651.60
828.20
Pretax Income
28,600.50
19,004.40
64,289.90
33,068.70
26,317.20
12,493.60
Income Tax
532.70
22.10
29.40
-
4,515.80
7,066.60
Consolidated Net Income
28,067.80
18,982.30
64,260.50
33,068.70
21,801.40
5,427
Net Income
28,067.80
18,982.30
64,260.50
33,068.70
21,801.40
5,427
Net Income After Extraordinaries
63,157.70
19,670.30
64,369.20
33,068.70
21,801.40
5,427
Net Income Available to Common
7,022.10
18,294.20
64,151.70
33,068.70
21,801.40
5,427
EPS (Basic)
23.70
30.92
23.21
3.19
1.45
0.33
Basic Shares Outstanding
294.80
590.20
2,763.60
10,348.90
14,958.70
16,440.80
EPS (Diluted)
23.82
30.99
18.73
3.10
1.46
0.32
Diluted Shares Outstanding
294.80
590.20
3,424.30
10,665.10
14,958.70
17,034.80
EBITDA
27,865.80
37,727.10
42,631.40
38,608.20
29,828.30
12,856.50
Non-Operating Interest Income
190.60
185.50
183.00
198.70
97.40
360.30

About AEterna Zentaris

View Profile
Address
315 Sigma Drive
Charleston South Carolina 29486
United States
Employees -
Website http://www.aezsinc.com
Updated 07/08/2019
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.